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Objectives
After completion of this program, the reader should be able
to:
1. Explain the processes of angiogenesis and tumorigenesis and the role of each in cancer metastasis.
2. Describe the actions of dopamine on tumorigenesis
and its relationship with vascular endothelial
growth factor.
3. Discuss the methodology and results of the initial
trials suggesting the use of dopamine and dopamine
agonists in cancer treatment.
4. Evaluate the potential use of dopamine for cancer
treatment in regard to side effect profiles and cost of
therapy in comparison to current angiogenesis inhibitors.
Abstract
In recent years, there have been numerous developments in
monoclonal antibodies used as anticancer drugs with a focus
on reducing the ability of cancers to metastasize and produce
new vasculature. These agents are called angiogenesis inhibitors and although these agents have been proven effective in
treating certain types of cancers, production and administration of monoclonal antibodies comes at a steep cost with a
severe side effect profile. Under normal physiologic conditions, angiogenesis is an important mechanism to create new
blood vessels from preexisting vessels, usually occurring in
adults. Tumor cells can hijack the angiogenesis pathway to
produce new distant tumors sites, which may lead to poor
prognosis. In an ongoing effort to discover alternative therapeutic options for cancer treatment, researchers have discovered that dopamine (DA) is able to inhibit angiogenesis
through a mechanism involving vascular endothelial growth
factor (VEGF) and the D2 receptors. When the D2 receptor is
activated, this causes the VEGF receptor 2 (VEGFR2) to undergo endocytosis thereby preventing VEGF binding and
stopping the creation of new vessels. Endocrine and gastrointestinal cancers have a high expression of Dz and VEGF receptors and therefore are potential targets of therapy. Although DA may provide better tolerability and cost benefits,
future studies in humans must be conducted to clearly determine its safety and efficacy as a treatment for cancer.
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Introduction
Angiogenesis is a natural process used by our bodies to produce new vasculature to increase blood flow to certain areas
which have need of additional oxygenation.1 When cancers
proliferate, an increased demand for energy emerges. Cancers utilize the process of angiogenesis to increase blood
flow to the area to allow for continued growth of a tumor in a
process known as tumorigenesis. Inhibiting this action is one
strategy of therapy used today to prevent further growth of
the cancer. Due to high costs of traditional angiogenic inhibitor therapy for cancer, other options are a welcome sight.
One option currently being studied is dopamine.
Angiogenesis and Tumorigenesis
Angiogenesis occurs in a four-step process: cellular injury,
migration, proliferation and survival. The first step can be
induced by a number of stimuli, including hypoxia.1 A hypoxic environment can be caused by lack of perfusion to a local
area, leading to a decrease in available oxygen and nutrients,
which in turn stimulates Hypoxia-Inducible Factor 1 (HIF-1),
a heterodimer consisting of an alpha and beta subunit.
Hypoxia-Inducible Factor 1 is stabilized by the hypoxic environment and binds to gene sequences that allow for the
upregulation of glucose transporters, erythropoietin and vascular endothelial growth factor (VEGF). Hypoxia-Inducible
Factor 1 also induces upregulation of the VEGF receptor
(VEGFR), namely VEGFR2, which is involved in the process of
angiogenesis. The VEGF /VEG FR complex is an important activator of endothelial cell function by a number of signal
transduction pathways, allowing for an increase in proliferation, permeability, migration and survival.
The VEGF /VEG FR complex also regulates the release of matrix metalloproteinases (MMPs), which degrade the basement membrane of the endothelial cells, enabling cellular
migration toward chemicals secreted from the hypoxic areas
through the process known as chemotaxis.2 A key agent in
angiogenic chemotaxis is VEGF. Cells are able to move by
using membrane projections consisting of actin-sensing
chemoattractants (filopodia) and the formation of a leading
edge of the cell by cytoplasmic actin (lamellipodia). Finally,
through a complex mechanism, endothelial cells arrive at the
hypoxic site and form a tubule stabilized by pericytes from
surrounding vasculature and differentiated mural cellsl.
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In tumorigenesis, the initial neoplastic lesion can only grow
between 2 to 3 mm3 because of the lack of vascularity and
the diffusion barrier of oxygen.1 To overcome this limitation,
the tumor must find a way to obtain access to vasculature in
order to continue its proliferation. The tumor is able to grow
through activation of the "angiogenic switch," occurring
when the inhibitory factors are outnumbered by the positive
factors, leading to development of new vascularization. The
p53 tumor suppressor gene normally works to inhibit excessive angiogenesis by blocking the expression of the necessary
growth factors, including VEGF; however, p53 is mutated and
inactivated in almost SO percent of cancer, rendering this
inhibitory pathway futile. Additionally, because the environment of tumors is likely hypoxic, there is often an overexpression of HlF-1 stimulating the release of VEGF-A, an
isoform of VEGF, and leading to the angiogenic sequences
described above. Because of the hyperexpression of VEGF-A,
Bcl-2 is also overexpressed in cancers and inhibits apoptosis
by maintaining mitochondrial membrane integrity by overwhelming the effects of Bax, which normally induces apoptosis.3 Additionally, survivin, usually a negligible protein in
healthy individuals, is overexpressed due to elevated VEGF-A
levels in cancers.1 Survivin is thought to inhibit caspase activity, an apoptosis inducing protease, adding a second mechanism for endothelial cell survival and tumorigenesis.
Introduction to Dopamine
Dopamine, also known as 3-hydroxytyramine, is a monoamine metabolic product of the amino acid tyrosine.4 It is stored
in vesicles located in the presynaptic terminals of neurons
after being taken in from the cytosol through the vesicular
monoamine transporter 2 (VMAT2).S Dopamine is released
into the synaptic cleft and exerts its actions by binding to
postsynaptic G-protein coupled receptors (GPCR) of two
different classes, which are differentiated based on their
biochemical effects and gene sequencing.6 It should also be
mentioned that DA has different affinities (nanomolar to
micromolar) for each receptor subtype which in turn has
implications on receptor subtype sensitivity to DA agonists
and antagonists.4 Remaining DA in the synapse can undergo
reuptake via the dopamine active transporter (DAT) back
into the presynaptic neuron or undergo enzymatic degradation by either monoamine oxidase (MAO) or catechol-omethyltransferase (COMT).
The Dl receptor class consists of the postsynaptic D1 and Ds
receptors and activates the Gas/olf protein family to increase
adenylate cyclase activation to produce cAMP. In contrast,
the Dz receptor class includes the Dz, D3 and D4 receptors,
with D2 and D3 located both presynaptically and postsynaptically.s These are coupled to the Gavo protein family that inhibit adenylate cyclase to decrease cAMP.4 By altering the
levels of cAMP, the activity of various downstream signaling
molecules are regulated.6 Additionally, there are routes of
dopamine receptor signaling that are independent of cAMP.
In fact, many intracellular signaling pathways can be mediated through various enzymes, such as ERK, Epac 1 and GRK 2.
In terms of expression, DA receptors are found both in the
central nervous system (CNS) and peripheral areas of the
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body.s Within the brain, dopaminergic neurons project to
four major DA pathways associated with learning, cognition
and motor function. In peripheral areas, the different subtypes are found on vascular smooth muscle, on various renal
and mesenteric arteries and in the endocrine system.7 Many
actions may result from DA binding, such as diuresis and natriuresis in the kidneys and regulation of norepinephrine
release. Dopamine receptors may play a role in the immune
system with nervous and renal inflammation and autoimmune
reactions. Lastly, another important result of receptor activation is the downstream effect of altering glutamate signaling.
Currently, DA and other agents that work by agonizing or
antagonizing its receptors are used to treat a variety of conditions, especially within the CNS. Dopamine precursors and
agonists are indicated in Parkinson's disease (PD) therapy
while DA antagonists are used as atypical antipsychotics for
schizophrenia.4 Other uses include the treatment of endocrine disorders, hypertensive crisis and as prokinetic agents.
Additionally, DA is utilized for its effect on alpha-receptors
and beta-receptors in the cardiovascular system for vasodilation and its inotropic effect on the heart.B This counteracts its
ability to induce NE release in the periphery for vasoconstriction. It is indicated for hypotension with bradycardia and
may be used in combination with other agents to treat postresuscitation shock. At higher doses, DA will cause systemic
and splanchnic constriction of the arteries. It may therefore
be used to increase renal blood flow for acute oliguric renal
failure and low cardiac output in critically ill patients.9 However, it has not been supported in trials for renal insufficiency
prevention or to decrease mortality or morbidity.10
More recently, the potential anticancer effect of DA has been
discovered and its role in treatment is being researched.6
Therefore, with the various existing therapeutic indications
for DA, it is widely available and determining its anticancer
effects may be useful in terms of costs, therapy management
and side effects.
Dopamine and VEGF
While already acknowledged as an important neurotransmitter in the CNS, it has been suggested that DA, acting through
the Dz receptor, can inhibit tumor growth by a number of
different pathways. One mechanism shows that DA increased
association between the Dz receptor and Sarcoma Homology
Phosphatase-2 (SHP-2) at the surface of the celJ.n The association stimulates the phosphorylation of SHP-2, inhibiting
activation of the VEGFR-2. Another theory suggests that DA
stimulation of the Dz receptor actually causes the endocytosis of the VEGFR-2, which prevents VEGF from binding and
causing its associated effects. 1 2 This demonstrates an association between the nervous system and angiogenesis that was
previously unknown. This allows for Dz receptor agonists
that are already in existence to be used in other clinical settings.
Evidence for the Use of Dopamine
The connection between DA and VEGF to the associated
effects on angiogenesis and tumorigenesis has prompted
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researchers to consider DA as a potential agent to target
these mechanisms which cancer cells use to thrive. It has
been found that DA selectively inhibits the actions of VEGF
by acting on the Dz receptor and/or causing endocytosis of
VEGFR-2. However, since this is a selective inhibition, other
modulators of angiogenesis are still promoting angiogenesis,
and the process is not completely inhibited.12,13 This selective
inhibition means there is room to study DA and Dz agonists
(since they both activate the DA receptors and have the similar effects) to see if its use can be successful in the treatment
of cancers.
Both an animal study utilizing rats and a small human study
were conducted to compare the outcome of treating ovarian
hyperstimulation syndrome (OHSS) when using cabergoline,
a long-acting Dz receptor agonist. Ovarian hyperstimulation
syndrome is caused when there is ovarian hypersecretion of
VEGF which activates VEGFR-2.14 The results of the study
showed a decrease in the incidence of OHSS in rats treated
with cabergoline (100 µg/kg/day) and, with the limited side
effects seen in the rodent trial, the researchers decided to do
a small trial on humans as well. For humans, cabergoline
treatment was given only to individuals who were oocyte
donors at high risk for developing the syndrome. The human
test subjects were being treated with prophylactic doses of
5 to 10 µg/kg/day of cabergoline. Results on humans showed
a 65 percent occurrence of OHSS in the control group compared with 25 percent in the treatment group. Since OHSS is
dependent upon high concentrations of VEGF, these results
show that activating the Dz receptor may possibly have beneficial effects to decrease the rate of angiogenesis and tumorigenesis in humans suffering from cancer. However, the
specifics about how the researchers performed this study,
the sample size and other parameters were not available at
the time of publication.
Another animal study showed that rats with a hyperactive
dopaminergic system had decreased tumor angiogenesis.1s
The researchers bred rats to have hyperactive dopaminergic
systems, a requirement for the study, and then implanted rat
adenocarcinoma cells into the rats in order to observe the
tumor growth. It was discovered that rats with hyperactive
dopaminergic systems had about 35 percent smaller tumors
compared to the placebo rats. Fewer lung metastases were
observed in the experimental group (hyperactive dopaminergic system rats) compared to the control group (nonhyperactive dopaminergic system rats) macroscopically after
all test rats had died. On the 24th day after implanting the
cancerous cells into the rats with either hyperactive or nonhyperactive dopaminergic systems, all rats with nonhyperactive dopaminergic systems had died and none of the rats
with hyperactive dopaminergic systems had died.
Most importantly, it was found that rats with hyperactive
dopaminergic systems had decreased tumor angiogenesis by
determining hemoglobin content in tumors from both groups
of rats. Hemoglobin content in tumors were significantly lower in rats with hyperactive dopaminergic systems compared
to those with nonhyperactive dopaminergic systems
(hyperactive: 40.6±7.6 mg/dL; nonhyperactive: 76.9±13 mg/
dL, P<0.05). The lower hemoglobin content in the tumor cor-
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responded to decreased tumor growth. No medication was
used in this study. The data gathered was based upon the
premise that rats with hyperactive dopaminergic systems
would have increased levels of DA in their system, allowing
for the effects of naturally produced DA to show its action.
This further suggests that DA has a mechanism by which angiogenesis is inhibited.
A study was conducted on gastric cancerous tissue in rats
and mice.16 Gastric cancer is known to require increased angiogenesis activity to survive and the possibility of using doses of DA to inhibit the growth of this cancerous tissue was
being examined. In the study, some rats and mice were
pretreated with domeperidone, a Dz receptor antagonist, to
confirm that the actions of DA were through the Dz receptor.
The researchers found that when rats or mice were pretreated with domeperidone followed by treatment with DA, there
was no effect, confirming that the Dz receptor is responsible
for the effects shown in the study. The results showed that
even low doses of DA (SO mg/kg/day or about 5 percent of
the median lethal dose in rodents) would inhibit the growth
of the cancer tumor substantially (tumor size: 311.5 ±
11.9mm3 in placebo group, 106.0 ± 7.4 mm 3 in treatment
group, P<0.05). What is even more interesting is that in all of
the samples of tissue examined, the concentrations of endogenous DA were very low, almost negligible, and the concentrations of VEGF were increased. Cancers deplete the stores
of DA in the tissue, allowing for the growth of the cancer with
increased expression of VEGF. This explains why even low
doses of DA would inhibit the growth of the cancer; the DA
administered to the site would be able to act on every receptor available since all or most of the endogenous DA was
gone. The DA would be able to endocytose many of the
VEGFR-2 and thereby decrease the angiogenic properties of
the gastric cancer.
Since human cancers utilize this same mechanism of angiogenesis to provide their sustenance, animal studies can provide a good basis for comparison. Human studies will need to
be conducted to confirm that this effect can be mirrored in
the human physiology and allow for this to be a treatment
option for those with cancers and tumors sensitive to DA therapy, such as endocrine tumors.17.1a Human studies will need to
be used to determine the dose of DA that may be administered
in treating cancers, as this is not known at this time.
A study was conducted to evaluate the prevalence of the D2
receptors and VEGF in various pituitary adenomas.19 Knowing this information would be beneficial in the plan to treat
patients with certain kinds of cancers, as it could tailor the
therapy to target a specific receptor if it is known to have
increased expression in that cancer. The study examined 197
tissue samples from patients with various types of pituitary
adenomas. A streptavidin-peroxidase method was used for
staining the samples of cancerous tissue obtained from the
patients. These stains were then scored on a 0 to 7 scale
which accounted for the strength of the stain (0 to 3, where 0
is negative, 1 is weak, 2 is medium, 3 is a strong stain) and
the extent of the stain (0 to 4, where a percentage of the
staining area compared to the whole carcinoma sample was
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evaluated; 0 (0 percent), 1 (1 to 25 percent), 2 (26 to SO percent), 3 (51 to 75 percent), 4 (76 to 100 percent)). Any score
above 3 was considered a high expression stain. Results
showed that 64.9 percent of the pituitary adenomas had a
high expression of Dz receptors and 58.9 percent had a high
expression of VEGF. From this data, it can be inferred that
over half of pituitary adenomas could potentially benefit
from DA therapy to decrease the cost of treatment and help
reduce tumor size, since these tumors would be more sensitive to treatment with DA due to high Dz receptor expression.
Side Effects
Side effects associated with the costly VEGF inhibitors can
include bleeding, clots that can lead to a stroke or heart attack, high blood pressure, proteinuria and gastrointestinal
disturbances. Rarer side effects can include GI perforation,
fistulas of the bile duct and even certain cancers. Birth defects have been seen in animal models, but have yet to be
seen in humans. Generally, VEGF inhibitors carry a larger,
more severe side effect profile that occurs more often than
with an agent like dopamine.20 Furthermore, because both
dopamine and VEGF inhibitors work via similar mechanisms,
treatment will require concurrent therapies with chemotherapeutic agents, like 5-Fluorouracil.2 1 The use of VEGF inhibitors could be problematic in patients suffering from cardiovascul~r conditions in addition to cancer, whereas DA or Dz
agonists could be a safer option in patients with or at risk for
cardiovascular complications.

While DA agonists may be considered as an anticancer treatment, the severity of side effects must be postulated from
their current indications in other therapies. Dopamine agonists have been observed to cause peripheral edema, orthostatic hypotension, hallucinations, sudden-onset of sleeping
("sleep attacks") and impulse control disorders (ICDs).22
Characteristics of ICDs include hypersexuality and compulsive eating, gambling and buying. This particular adverse
effect has been found in 17 percent of PD patients taking DA
agonists and may eventually have other negative consequences relating to finance, behavior and social relationships. Addressing these effects includes either discontinuing
or tapering DA therapy. Strategies for tapering may include
substituting other medications such as L-dopa; however, this
may worsen the disease being treated. Furthermore, tapering
may be ineffective in some patients and can result in dosedependent dopamine agonist withdrawal syndrome (DAWS).
Dopamine agonist withdrawal syndrome has been characterized by both psychological and physical symptoms including
anxiety, panic attacks, depression, agitation, fatigue, flushing,
nausea and vomiting. These symptoms are similar to withdrawal from other psychostimulants. Additionally, there is
currently no treatment for the syndrome and the only way to
alleviate DAWS is by restarting or increasing the DA agonist
therapy. Therefore, to prevent DAWS, prevention strategies
must be in place before beginning therapy. It is recommended to remain cautious with patients with a high risk of ICD
because this side effect is highly associated with DAWS. Additionally, patients should avoid using high doses of DA agonists for long periods of time as this is a risk factor for ICD.
Therefore, patients must provide informed consent and beSpring 2015 Volume 6, Issue 2
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come educated on the potential consequence of DAWS. They
also should be screened for ICD risk during therapy and report any !CD and DAWS symptoms right away.
An animal model examining endometrial angiogenesis used
DA agonist cabergoline and observed reduced neoangiogenesis.z3 It was noted that DA safety considerations needed to be
studied in the future since DA therapy may interfere with
pregnancy. Researchers noted that lower doses of 0.05 mg/
kg cabergoline were as effective as higher doses of 0.1 mg/
kg, implying that using the lowest effective dose may help
lower the incidence of side effects if used in humans.
Although dosing has not yet been established for DA in
anticancer treatments in humans, this may be a dosing
consideration in terms of maximizing efficacy while minimizing side effects.
Even with the concern for DAWS, DA agonists have already
been used for a length of time, making their side effects well
known and manageable, and can be generally considered
safe.24 However, addressing side effects by tapering therapy
may not be practical in cancer treatment. Therefore, the risk
of DA side effects must be sufficiently studied when DA is
used at anticancer doses in humans.
Cost Implications
One of the major barriers of utilizing newer anticancer treatments, especially monoclonal antibodies, is the price associated with them. For example, one study looked into the cost
of three angiogenesis inhibitors: the VEGF inhibitor bevacizumab (Avastin) and two protein kinase inhibitors, sunitinib
(Sutent) and sorafenib (Nexavar). It found that the perpatient per-month cost associated with these three medications was: $5,639 for sunitinib, $5,214 for sorafenib and
$13,664 for bevacizumab. 25 These prices do not include the
costs of additional procedures and/or the treatments related
to the adverse events. However, for a vial of 400mg/SmL DA
the hospital cost is around 50 cents per vial, which is 10,000
times less expensive than the angiogenesis inhibitors.26 For
the Dz agonist cabergoline, the daily cost is between $10 and
$15, so the cost per month would be roughly $300 to $450.27
With the significant cost differences between DA and VEGF
inhibitors, this provides an added benefit to its potential anticancer effects.
Conclusion
From the limited number of animal studies currently published, it seems that treatment with DA and D2 agonists potentially has a great benefit in patients with cancers known
to have high expression of Dz receptors, such as endocrine
tumors and gastrointestinal tumors. While large human studies have yet to be performed, there is strong evidence from
the animal studies and the small human study that DA and Dz
agonists decrease the effects of the VEGFR-2 and inhibit angiogenesis and tumorigenesis. Applying this to cancer treatment regimens could lead to decreased costs for health care
systems and reduced adverse events, as DA and 0 2 agonists
are less expensive and potentially safer options compared to
the conventional angiogenesis inhibiting regimens. Since the
first priority of health care is the safety and well-being of the
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patient, despite the initial promise of using DA and Dz agonists for cancer treatment, it cannot be fully recommended
until additional research is completed. Future trials with humans must be conducted to determine the full spectrum of
safety, dosing and efficacy of utilizing DA as a potential new
anticancer treatment.
References
1.
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De
Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580.
2.
La malice L, Le Boeuf F, Huot J. Endothelial Cell Migration During Angiogenesis. Circ Res 2007;100: 782-794
3.
Elmore S. Apoptosis: a review of programmed cell death. Toxicol.
Pathol. 2007;35, 495-516.
4.
Beaulieu J. Gainetdinov R. The physiology, signaling, and pharmacology
of dopamine receptors. Pharmacological Rev. 2011 Mar; 63(1) : 182217.
5. Bolnoldi I, Howes 0 . Presynaptic dopaminergic function: implications
for understanding treatment response in psychosis. CNS Drugs. 2014
Jun 12; 28(1): 649-63.
6. Beaulieu j, Espinoza S, Gainetdinov R. Dopamine receptors - IUPHAR
review 13. British journal of Pharmacology. 2014 Nov 24; 172: 1-23.
7.
Mascia A, Afra J. Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological. and therapeutic data.
Cephalagia. 1998 May; 18: 174-82.
8.
ECC Guidelines. Circulation. 2000 Aug 22; 102: 1-129.
9.
Olsen N. Effects of dopamine on renal haemodynamics tubular function
and sodium excretion in normal humans [abstract]. Dan Med Bull. 1998
Jun; 45(3) 282-97.
10. Needham E. Management of acute renal failure. Am Fam Physician.
2005Nov1; 72(9): 1739-46.
11. Sinha S, Vohra PK, Bhattacharya R., Dutta S, Mukhopadhyay D. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Srchomology-2-domain-containing protein tyrosine phosphatase 2. j Cell
Sci. 2009;122(18):3385-3392.
12. Basu S, Nagy IA. Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ.
Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/
vascular endothelial growth factor. Not Med 2001; 7: 569-74.
13. Mayo Clinic- Research [Internet]. Mukhopadhyay D. Tumor Angiogenesis and Vascular Biology. Mayo Foundation for Medical Education and
Research. Available from: www.mayo.edu/research/labs/tumor-angio
genesis-vascular-biology/dopamine-inhibition-angiogenesis-via-vegf.
l4. Gomez R, Gonzalez-Izquiredo M, et al. Low-Dose Dopamine Agonist
Administration Blocks Vascular Endothelial Growth Factor (VEGF)Mediated Vascular Hyperpermeability without Altering VEGF Receptor
2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation
Model. Endocrinology: July 27, 2006. 147; 11. Published Online July 01,
2013.
15. Teunis M, Kavelaars A, et al. Reduced tumor growth, experimental
metastasis formation, and angiogenesis in rats with a hyperreactive
dopaminergic system. FASEB ]. September 2002. 16:1465-1467;
doi:l0.1096/fj.02-0145fje.
16. Chakroborty D, Sarkar C, et al. Depleted dopamine in gastric cancer
tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res. July 1, 2004. 10:4349-4356;
doi: 10.1158/1078-0432.CCR-04-0059.
17. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability
factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am] Pathol. 1995;146(5):1029-1039.
18. Gatto F, Hofland L. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocrine-Related Cancer. 2011; 18(6):233251.
19. Wang Y, Li j, Ma C, et al. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary
adenomas: a study of 197 cases and indications for the medical therapy. journal Of Experimental & Clinical Cancer Research: CR [serial online]. July 16, 2014;33:56. Available from : MEDLINE with Full Text, Ipswich, MA.
20. National Cancer Institute [Internet]. Bethesda (MD): National Institutes
of Health; cl 997-2004. Angiogenesis Inhibitors; [updated 2011 Oct 7;
cited 2015 Mar 27]; Available from: www.cancer.gov/cancertopics/

16

21.

22.
23.

24.

25.

26.

27.

THE PHARMACY AND WELLNESS REVIEW

treatment/types/biological-therapies/angiogenesis-inhibitors-factsheet.
Sarkar C, Chakroborty D. Dasgupta PS, Basu S. Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. /ntj Cancer. Forthcoming. doi: 10.1002/ijc.29414.
Nireberg M. Dopamine Agonist Withdrawal Syndrome: Implications for
Patient Care. Drugs & Aging. 2013 May;30: 587-92.
Novella-Maestre E, Carda C, Inmaculada N, et al. Dopamine agonist
administration causes a reduction in endometrial implants through
modulation of angiogenesis in experimentally induced endometriosis.
Human Reproduction. 2009 Feb 3 [cited 2015 Mar 28]; 24(5): 1025-35.
Available from: humrep.oxfordjournals.org/content/24/5/1025.full.
pdf+html.
Sarkar C, Chakroborty D, Basu S. Neurotransmitters as regulators of
tumor angiogenesis and immunity: the role of catecholamines.] Neuroimmune Pharmacol. 2013; 8: 7-14.
Choueiri TK, McDermott D, Duh MS, Sarda SP, Neary MP, Oh WK Costs
associated with angiogenesis inhibitor therapies for metastatic renal
cell carcinoma in clinical practice: Results from a medical chart review
study. Urol Oneal. 2012; 30:848-855.
Varriale P, Mossavi A. The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function? Clin Cardiol.1997;20:627-630.
Smala AM, Spottke EA, Machat 0, et al. Cabergoline versus levodopa
monotherapy: a decision analysis. Mov Disord 2003; 18: 898-905.
The authors have no conflict of interest or funding support to disclose.

Spring 2015 Volume 6, Issue 2

Potential Use of Dopamine and Dopamine Agonists as Angiogenesls Inhibitors in the Treatment of Cancer

Oncology

Assessment Questions
1.

Referring to OHSS, which of the following doses were
used in humans who were oocyte donors at high risk for
developing the syndrome?
A 100 µg/kg/day
B. 150 µg/kg/day
C. Prophylactic doses of 5-10 µg/kg/day
D. Prophylactic doses of 50-100 µg/kg/day

2.

Rats with hyperactive dopaminergic systems had tumors
which w_ere what percent smaller in size compared to
the nonhyperactive dopaminergic system rats?
A
B.

7.

The mechanisms in which dopamine inhibits VEGF
receptors include:
A SHP-2
B. Receptor Endocytosis
C. AandB
D. None of the above

8.

Which of the following drugs may be used to block
the D2 receptor?
A Dopamine
B. Cabergoline
C. Domeperidone
D. All of the above

9.

The treatment for DAWS includes:
A. Antidopamine therapies
B. Risperidone
C. Apomorphine
D. Currently no treatment is available

12%
30%

c. 56%
D.
3.

4.

5.

6.

35%

Which two types of cancer have shown to have a high
expression of D2 receptor density?
A Lung and Prostate
B. Endocrine and Gastrointestinal
C. Breast and Testicular
D. Pancreatic and Gastrointestinal

10. Dopamine's effects are mostly observed in:
A The central nervous system
B. The cardiovascular system
C. The pancreas
D. Both A and B

Angiogenesis involves which of the following steps:
A Migration
B. Proliferation
C. Cellular injury
D. Survival
E. All of the Above
The overexpression of which growth factor is primarily
behind angiogenesis?
A Growth Differentiation Factor 9
B. Vascular Endothelial Growth Factor
C. Transforming Growth Factor Alpha
D. Migration Stimulating Factor
VEGF inhibitors carry no cardiovascular side effects.
A True
B. False
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To receive continuing education credit for this program, visit www.onlLedu/pharmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:

Office of Continuing Education at the Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

Program Title: Potential Use of Dopamine and Dopamine Agonists as Angiogenesis Inhibitors in the Treatment of Cancer
UAN: 0048-0000-15-208-HOl-P CEUs: 0.1 for pharmacists only

All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit. Certificates will be distributed as a PDF document to a valid email address.
Name:
Address:
City:

State:

Phone:

Email:

Pharmacy License #:

State:

Zip:

y

ONU Alumni?

N

1

2

3

4

5

Explain the processes of angiogenesis and tumorigenesis and the role
of each in cancer metastasis.

1

2

3

4

5

Describe the actions of dopamine on tumorigenesis and its relationship with vascular endothelial growth factor.

1

2

3

4

5

Discuss the methodology and results of the initial trials suggesting
the use of dopamine and dopamine agonists in cancer treatment.

1

2

3

4

5

Evaluate the potential use of dopamine for cancer treatment in
regard to side effect profiles and cost of therapy in comparison to
current angiogenesis inhibitors.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program objectives were clear.
The program met the stated goals and objectives:

Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer

1.

A B

2.

A B

3. A B

c
c
c

D

4. A B

D

5.

D

6. A B

A B

c
c

D E

7. A B

D

8. A B

Any questions/comments regarding this continuing education program
can be directed to Lauren Hamman, Advanced Administrative Assistant
for the Office of Continuing Education (email: 1-hamman@onu edu,
phone 419-772-2280).

9.

A B

c
c
c

~

D

10. A B

c

D

D

D
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